Bluefin Capital Management, LLC Eli Lilly & CO Transaction History

Bluefin Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$321.55 - $374.67 $353,705 - $412,137	-1,100 Reduced 55.0%	900 $329,000
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $592,960 - $675,740	2,000 New	2,000 $647,000
Q1 2022 May 16, 2022	SELL	$234.69 - $291.66 $812,027 - $1.01 Million	-3,460 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$224.85 - $279.04 $323,784 - $401,817	1,440 Added 71.29%	3,460 $956,000
Q3 2021 Nov 15, 2021	BUY	$221.6 - $272.71 $447,632 - $550,874	2,020 New	2,020 $467,000
Q1 2021 May 17, 2021	SELL	$164.32 - $212.72 $213,616 - $276,536	-1,300 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$130.46 - $172.63 $169,598 - $224,419	1,300 New	1,300 $219,000

4,007

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Bluefin Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bluefin Capital Management, LLC with notifications on news.